Allogene Therapeutics (ALLO) Enterprise Value (2018 - 2026)
Allogene Therapeutics (ALLO) posted Enterprise Value of -$261.6 million for Q1 2026, down 4.56% sequentially from -$250.2 million in Q4 2025, and up 6.57% YoY from -$245.5 million in Q1 2025.
Allogene Therapeutics (ALLO) Enterprise Value (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Enterprise Value for 9 years, with the latest figure at -$261.6 million in Q1 2026.
- Quarterly Enterprise Value rose 6.57% year-over-year to -$261.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$261.6 million (up 6.57% YoY) and the FY2025 annual result came in at -$250.2 million, up 14.45% from the prior year.
- Enterprise Value eased to -$261.6 million in Q1 2026 per ALLO's latest filing, from -$250.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$250.2 million in Q4 2025 and troughed at -$552.2 million in Q3 2022.
- A 5-year average of -$384.7 million and a median of -$435.5 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value fell 28.95% in 2022, then surged 38.93% in 2024.
- Over 5 years, Enterprise Value stood at -$467.2 million in 2022, then advanced by 4.94% to -$444.1 million in 2023, then jumped by 34.14% to -$292.5 million in 2024, then climbed by 14.45% to -$250.2 million in 2025, then declined by 4.56% to -$261.6 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$261.6 million, -$250.2 million, and -$252.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -332.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -332.60 Mn |
| Mar 31, 2026 | -261.63 Mn |
| Dec 31, 2025 | -250.21 Mn |
| Sep 30, 2025 | -252.19 Mn |
| Jun 30, 2025 | -273.12 Mn |
| Mar 31, 2025 | -280.04 Mn |
| Dec 31, 2024 | -292.48 Mn |
| Sep 30, 2024 | -284.30 Mn |
| Jun 30, 2024 | -435.50 Mn |
| Mar 31, 2024 | -378.84 Mn |
| Dec 31, 2023 | -444.08 Mn |
| Sep 30, 2023 | -465.51 Mn |
| Jun 30, 2023 | -491.96 Mn |
| Mar 31, 2023 | -471.22 Mn |
| Dec 31, 2022 | -467.18 Mn |
| Sep 30, 2022 | -552.23 Mn |
| Jun 30, 2022 | -490.49 Mn |
| Mar 31, 2022 | -449.05 Mn |
| Dec 31, 2021 | -399.86 Mn |
| Sep 30, 2021 | -428.27 Mn |